The punching bag of new medications takes another hit:
Analysts were forecasting blockbuster annual sales of $2bn (£1.01bn, E1.49bn) for the insulin spray. It delivered just $4m in the second quarter of 2007 ““ the first time Pfizer disclosed sales of the product.
Related posts:
- Desperate Pfizer going with ads to save failing Exubera
- Exubera: A total failure
- ADA on Exubera
- Exubera linked to lung cancer?
- Why Exubera failed
- Pharmaceutical sales reps on MySpace
- The Exubera autopsy
KevinMD.com on Facebook
 
Follow on Twitter  
Subscribe





Comments on this entry are closed.